News
Lorlatinib showed significant benefit in 1st line treatment of advanced ALK-positive non-small cell lung carcinoma
In the international CROWN study, lorlatinib compared to crizotinib led to a 72% reduction in the risk of disease progression or death and significant improvement in intracranial response to treatment in previously untreated patients with advanced ALK-positive non-small cell lung carcinoma (NSCLC). The results were published in November 2020 in the prestigious New England Journal of Medicine.
Position of Parenteral Therapy in Patients with Severe COVID-19 Disease
Patients with severe COVID-19 disease are at risk of developing acute respiratory insufficiency…
Prevalence of Depression, Anxiety, and Stress in the Global Population During the COVID-19 Pandemic
A cross-sectional study assessed the prevalence and rate of depression, anxiety, and stress among…
Does idarucizumab reverse the anticoagulant effect of dabigatran regardless of renal function?
The drugs idarucizumab and dabigatran are excreted by the kidneys. The RE-VERSE AD study…
Profile of the effect of aclidinium bromide compared to glycopyrronium bromide
A study by Spanish authors examined the profiles of 2 long-acting muscarinic receptor antagonists…
Genuair®/Pressair® Inhaler in the Treatment of COPD – Minimum Errors During Inhalation and High Patient Satisfaction
The article by German authors summarizes the results achieved with the Genuair® inhaler (marketed…
The Importance of Vitamin D for the Proper Function of the Immune System
The relationship between vitamin D and the immune system has been known for nearly 30 years, but…
Summary of Recommendations for the Treatment of Immune Thrombocytopenia in Pregnancy
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a temporary or permanent…
Teriflunomide and Pregnancy Planning
The authors of the article published last year in Multiple Sclerosis Journal present data regarding…
Interactive Case Study of a Patient with Severe Hemophilia A - Experience from Slovenia
Assoc. Prof. Dr. Irena Preložnik Zupan (University Medical Centre Ljubljana) describes an interactive...